www-com-develops-34.html
Novo Annual Report 2015
35 / 72
merus is a clinical-stage
com
pany developing fully human bi- specific antibodies for various oncology treatments. the two lead programmes are for solid tumours and acute myeloid leukemia.
www
.merus.nl nkarta therapeutics is focused on developing natural killer (nk) cell-based therapies for use in the treatment of cancers. obseva
develops
innovative drugs for women?s reproductive medicine.
www
.obseva.
com
orphazyme
develops
novel therapeutics for the treatment of lysosomal storage diseases. the
com
pany is undertaking a clinical trial in niemann-pick disease type c.
www
.orphazyme.
com
panoptica
develops
a novel topical drug for wet age-related macular degeneration. the lead programme is in phase 1b clinical development.
www
.panopticapharma.
com
procept biorobotics
develops
a new treatment for benign prostate hyperplasia based on image guided and robot- controlled water ablation of prostate tissue. the device is ce marked and a regulatory study is underway in the us.
www
.procept-biorobotics.
com
ra pharmaceuticals focuses on developing peptide- based drugs for treatment of diseases of
com
plement dysregulation. the lead programme is an anti c5
com
plement inhibitor.
www
.rapharma.
com
reata pharmaceuticals
develops
new drugs for the treatment of inflammatory diseases and cancer. the lead programmes are in phase 2 clinical development.
www
.reatapharma.
com
si-bone is a revenue-stage medical device
com
pany that
develops
and markets new therapies for patients with low back pain related to sacroiliac joint disorders.
www
.si-bone.
com
tarsa therapeutics
develops
an oral calcitonin for the treatment of osteoporosis. the
com
pany submitted an nda for tbria tm in 2015.
www
.tarsatherapeutics.
com
unchained labs
develops
and markets life science tools. the
com
pany focuses on analysing and predicting stability of
com
plex protein therapeutics formulations.
www
.unchainedlabs.
com
unum therapeutics
develops
proprietary antibody- coupled t-cell preceptor technology for use in new cellular immunotherapies for cancer. the lead programme is in clinical testing.
www
.unumrx.
com
vantia therapeutics
develops
a small molecule agonists of vasopressin receptors. the lead asset has
com
pleted phase 2 clinical development for the treatment of nocturia in men with prostatic hyperplasia and will enter phase 3 in 2016 following
com
pletion of a thorough qt study.
www
.vantia.
com
vasculox
develops
a portfolio of anti-cd47 therapeutic antibodies for the treatment of cancer and pulmonary hypertension. the lead programme is in pre-clinical development.
www
.vasculox.
com
nkarta therapeutics novo ventures annual review 2015 35
www-com-nasdaq-36.html
